Back    Zoom +    Zoom -
ALI HEALTH Sets Up Task Force to Centrally Direct 'B2C+O2O' Pharm Biz Segment
Recommend
20
Positive
33
Negative
13
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Gold ETF share!
ALI HEALTH (00241.HK) Chairman and CEO Shen Difan revealed at the FY2026 results analyst conference call that the company will establish a dedicated task force to centrally direct its "B2C+O2O" pharmaceutical business segment, aiming to enhance close collaboration and generate synergies while gaining insights into refined healthcare demand across tens of thousands of grids nationwide.

ALI HEALTH last quoted at HKD4.23, down 6.83%, with turnover of 293 million shares, involving HKD1.259 billion.

Related News HSBC Research Cites Experts: TENCENT (00700.HK) and BABA-W (09988.HK) Benefit from Ecosystem Advantages

AASTOCKS Financial News
  • Remark
  • (1) HK Indices are real time
Home|RT Quote|Market|News|Indices
Feedback|Disclaimer
View: Mobile|Desktop
Lang: 繁|简|EN
Back To Top
Contact Us
Email: support@aastocks.com